A phase I/II trial of ECT 100 in patients with acute myeloid leukemia and other malignant blood disorders

Trial Profile

A phase I/II trial of ECT 100 in patients with acute myeloid leukemia and other malignant blood disorders

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2015

At a glance

  • Drugs ECT 100 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Dec 2015 New trial record
    • 21 Dec 2015 According to an ExCellThera media release, the Health Canada has approved the initiation of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top